Revolution Medicines, Inc.
RVMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The $45.01B market capitalization puts RVMD squarely in large-cap range for its industry. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Market Cap
$45.01B
Beta
1.41
P/E (TTM)
—
P/E (Fwd)
-35.90
EPS (TTM)
$-8.86
EPS (Fwd)
$-5.85
ROE
-79.1%
ROA
-30.1%
Cash
$3.94B
Total Debt
$1.19B
Free CF
-$711.6M
52W Change
411.5%
Annual Financials
Cash vs Debt
Where RVMD stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, RVMD finished 42.91% above its 150-day moving average ($146.85) and 59.10% above its 200-day moving average ($131.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RVMD overbought or oversold?
At the September 2, 2026 close, RVMD's RSI(14) was 54.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $3.94B in cash and $1.19B in debt, RVMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$711.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -79.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $29.4M (2021) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, RVMD has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RVMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.